New pan JAK inhibitors! Pfizer and theravance biopharma have reached a strategic cooperation to develop skin targeted local anti-inflammatory drugs!

December 26, 2019 / Biovalley bio on / -- Pfizer and theravance biopharma recently jointly announced that they have signed a global license agreement on the pre clinical project of the skin targeting, local effect and fast metabolism pan Janus kinase (Pan JAK) inhibitor of theravance biopharma The project targets proven pro-inflammatory pathways and is specifically designed to have skin selective activity and minimize systemic exposure Under the terms of the agreement, theravance biopharma will receive a $10 million cash advance and be eligible to receive up to $240 million in development and sales milestone payments from Pfizer In addition, theravance biopharma is eligible for royalties based on net sales worldwide for any potential products generated by the project Michael Vincent, chief scientific officer of Pfizer's inflammation and immunology, said: "the theravance biopharma's skin targeted JAK inhibitor project will well complement Pfizer's preclinical and clinical stage molecular combinations, which have unique selectivity and match those diseases that we believe are most likely to meet the unmet needs Local JAK inhibitors, which can be metabolized rapidly, have the potential to benefit more patients with mild to moderate skin diseases, and the current treatment options for such patients are limited " "We believe that this global agreement with Pfizer further validates our unique expertise in the discovery and development of innovative, organ selective JAK inhibitors," said Rick e Winningham, CEO of theravance biopharma As a clear global leader in the field of JAK inhibition, Pfizer is an ideal partner to promote our company's skin targeted pan JAK inhibitor project and release its therapeutic potential " On organ selective pan JAK kinase inhibition: JAK inhibitors play a role by inhibiting the activity of one or more enzymes of Janus kinase family (Jak1, JAK2, JAK3, Tyk2), which play a key role in cytokine signaling Inhibition of these JAK enzymes interferes with JAK / STAT signaling pathway, and then regulates the activity of various proinflammatory cytokines Currently, JAK inhibitors have been approved for the treatment of a range of inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, myelofibrosis and ulcerative colitis Source of the original text: theravance biopharma and Pfizer Inc enter global license agreement for skin-targeted, locally-acting pan-janus kiss (JAK) initiator program